POSEIDON - Prevalence of systemic inflammation in patients with atherosclerotic cardiovascular disease and heart failure

POSEIDON - Prevalence of systemic inflammation in patients with atherosclerotic cardiovascular disease and heart failure - POSEIDON

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-jRCT1070230051

Enrollment

1500

Registered

2023-08-23

Start date

2023-08-23

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerotic cardiovascular disease and Heart failure Atherosclerotic cardiovascular disease, Heart failure, ASCVD, HF

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: Participants are eligible to be included in the study only if all the following criteria apply: 1. Informed consent obtained before any study-related activities. Study-related activities are any procedures that are carried out as part of the study. 2. Age 18 years or above at the time of signing the informed consent. 3. Presence of ASCVD and/or HF. 4. Presence of serum creatinine in the medical chart within 24 months prior to signing of informed consent (for ASCVD patients only).

Exclusion criteria

Exclusion criteria: Patients are excluded from the study if any of the following criteria apply: 1. Previous participation in this study. Participation is defined as having given informed consent in this study. 2. Current participation (i.e., signed informed consent) in any other interventional clinical study. 3. Any hospitalization or unplanned visit within the last 60 days (including exacerbation of chronic disease with hospitalization). 4. Clinical evidence, or suspicion of, active infection within the last 60 days. 5. Mental incapacity, unwillingness, or language barriers precluding adequate understanding or cooperation.

Design outcomes

Primary

Measure	Time frame
Elevated hsCRP defined as hsCRP >=2 mg/L (yes/no) (Count of patient)	—

Secondary

Measure	Time frame
Secondary endpoints - IL-6 measures (pg/ml) - NT-proBNP measures (pg/ml) Exploratory endpoints - Demography, medical history, clinical, laboratory and pharmacotherapy data - FIB-4 index (score) - ELF score (score)	—

Countries

Argentina, Australia, Brazil, Canada, China, Czech Republic, Denmark, France, Germany, Hungary, India, Italy, Japan, Norway, Poland, South Korea, Sweden, United Kingdom, United States

Contacts

Public ContactKoichi Ishizaki

IQVIA Services Japan K.K.

koichi.ishizaki@iqvia.com+81-80-4731-0584

Outcome results